PCVX

At a glance

Vaxcyte, Inc. (PCVX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in San Carlos, United States and has 507 employees. The company is worth $9.89B. The share price is 30.7% below its 52-week high of $90.75. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Lee Ainslie (Maverick Capital), at $93.78M. In that quarter, 3 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $3.34M of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$9.89B

P/E

—

Forward P/E

—

P/B

3.3x

Dividend yield

0.00%

Payout

—

EPS

-$7.62

ROE

-36.51%

Profit margin

0.00%

Revenue growth

—

Beta

1.23

52-week high

$90.75

52-week low

$39.87

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• LA
  Lee Ainslie+ Added

  Maverick Capital · Q2 2026
  $93.78M

  1.61M shares · 0.8% of portfolio
• TS
  Two Sigma+ Added

  Two Sigma Investments · Q2 2026
  $15.92M

  273.88K shares · 0.0% of portfolio
• IE
  Israel Englander− Reduced

  Millennium Management · Q2 2026
  $7.94M

  136.63K shares · 0.0% of portfolio

Indicators, year by year

The last 6 closed years, each at that year’s closing price and reported numbers.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company